NEJM spotlights trials of transdermal estradiol patches in locally advanced prostate cancer, while Martha Gulati argues it’s unacceptable that rigorous RCT evidence for menopause hormone therapy in women still lags.
Among men with locally advanced prostate cancer, transdermal estradiol was noninferior to LHRH agonists for 3-year metastasis-free survival and led to a lower incidence of hot flashes but a higher incidence of gynecomastia.
We keep rediscovering the same truth—hormonal biology works. Estrogen returns in prostate cancer, this time via patches, with noninferior outcomes and potentially better tolerability.
🔑tE2 patches are noninferior to LHRH agonists for metastasis-free survival (n=1,360)
✅ 87.1% vs 85.9% 3-yr MFS
Whoa.....what's old is new again!
“Among men with locally advanced prostate cancer, transdermal estradiol was noninferior to LHRH agonists for 3-year metastasis-free survival”
“led to a lower incidence of hot flashes but a higher incidence of gynecomastia.”
“We keep rediscovering the same truth—hormonal biology works.”
“Estrogen returns in prostate cancer, this time via patches, with noninferior outcomes and potentially better tolerability.”
“Whoa.....what's old is new again!”
tE2 patches are noninferior to LHRH agonists for metastasis-free survival
87.1% vs 85.9% 3-yr MFS
Way fewer hot flashes (44% vs 89%)
“Original Article: Transdermal Estradiol Patches in Locally Advanced Prostate Cancer (STAMPEDE-1 and PATCH trials)”
“It is good we can do RCT studies on transdermal #estrogen….on men…”
“When will we do the right randomized controlled trials in women?”
“Do they deserve the information they need to make informed choices about their health during #menopause?”
This finding is one of many signals tracked across Healthcare. The live feed updates every few hours with new expert voices, debates, and emerging ideas.
← Back to Healthcare